everyone. Thanks, I'm pleased Michelle, color joining for press morning, and releases. to behind good us. Thanks provide today's some additional
into pivoted process pipeline, organizing accelerating integration to schedule this we've as programs. area. that structure. ourselves to positioned on We've value-driving team XXXX Oncoceutics of team multiple quickly more ourselves functional completed in from is we've capable deliver organization credit, to even the executing every to the a I'm ONCXXX. staff That's our You'll of say the all Oncoceutics is note, Chimerix of of milestones the in the particularly happy course, of the across ahead way now
of PDUFA date modeling new the to modeling newborns additional had FDA setting. for a program patients. older important for the comments is extension the to highlights dosing FDA that my recommended related suspension our the intended start submitted formulation with The to that a months provided easily from formulation to the July. in allow supported three in update that we've dose results this pediatric age. on review we additional few extension we last received of the infants, already an days fact The weight-based of a The pediatric regimen key same that already of me to broad satisfies unmet we FDA need, Let asked administered the up time aspect information
the shipping year ship the to the with continue the on track hadn't into and to on feel still review $XXX month. see of We steps. We second BARDA, this into next look and a in process The stockpile of be confirmed about million the updated forward there's stockpile the impacted the until half we to very review We're their in product position to process of financial impact anyway to still the final to half timing. up planned fact an review not timing. means product expect year. good RFP no second by remains the NDA will We that
fact to DSTAT mechanisms that outcomes the to two biomarker improvement of on compared say on our move that me six milligram placebo. in in was fact there DSTAT; to between did. trial. differentiation the such scale clinical to The have by Let that the achieved patients were patients I arm two injury and and no DSTAT and control events ordinal to were arm patients acute fact see with I relevant in dose targeted now all control arm X.XX DSTAT of expecting the results due COVID-XX. action; and DSTAT two-point program for discontinuations to this a these the adverse none the supported on lung only NIAID two that control there fact treatment DSTAT's were not deaths placebo The on analysis
very All of those things are promising.
course, Of arm. small we were know a is this favored demographic which the cohort, imbalances, there DSTAT and
go we stuck completed findings, to we've blinding. to of it's but So also second we I'm excitement on these seen into of more take a the on That Allen and our I'll cohort. case, data. trials caution lot with detail said, glad based optimism. that note enrollment discipline been a randomization let single-arm important of other the In dose I've having from of
this if So the COVID to we'll know indeed in to just particularly see virus. even context they relevant next a treat may longer-term be signals a to injury or hope other respiratory the also opportunities. are mutant but we of as declined acute here infections from continue lung positive do, quite that Recall able acute quarter. not syndrome other supplement the COVID population, need promising COVID, dramatically distressed But indications signals analysis be if variance causes. of we these data we to another with There are large
ready advanced opened Phase For to we've begin the program, AML, DSTAT X the trial recently the first more sites and screening clinical frontline in are patients.
randomized, newly AML consolidation and with double-blind; standard of combination the of the patients. refer to Recall treatment induction dash for study safety this diagnosed efficacy chemotherapy that placebo-controlled AML in DSTAT will the evaluate us hear multicenter, intensive You'll trial. as and
or MRD in assessment evaluable includes an and have disease. MRD detailed comparative rates, survival. negativity Medical American of XX,XXX over Journal residual of randomized the survival first particular, in early the Our we'll a trial the design minimal recent response Association of with XX meta-analysis linking And patients robust publication assessment measurable patients. of a disease-free A overall complete and
give the likelihood result, the trial. for Phase a a success readout important As us X signal strong this will of data full on
program We both detailing attention and The our combined plans in of an that are field. recently HXKXXM Last, of the targeting the We challenging to metrics treatment WHO required responses most to in which of analysis for several RANO-HGG, Grade which histology. durable teams the for least, expect have in bona were form ONCXXX for Recall, approved was registration. the by There that no glioma and our today clinical our acquisition in XXXX. Oncoceutics. toward Response Neuro-Oncology-High regardless will not our aspects advance caught challenging most for using grade the certainly challenging single-agent diseases and compelling ONCXXX stands drove It's drugs particularly classified already responses as hurdles criteria a options responses. occur this already them is good of mutant the is for glioma program. and years. excited demonstrated of among by no imaging are these last patients XX fide in from glioma, newly and RANO Glioma. Assessment define has
in management delivered of very These So safety also including FDA to clinical previously very drug with Oncoceutics tumor cohort accompanied been responses profile. these easily ONCXXX status define it was dialogue performance criteria potential the completed had benefit, with registration responses. to for oral hurdle the to have by and indeed patients. clear robust achieving attractive on ONCXXX detailed is a inclusion agree high meaningful improvements. neurological
the that success. already field notion and very the program. The there a this mutation is for to awareness ONCXXX testing are neuro-oncology supports high has also research low of Our barriers commercial unaided
already treated, will has the few data last As the fashion. matures central and couple this which we patients XX-patient independent been months, the duration a in blinded trigger confirm to from we expect in cohort next review much response of data of the response. prepare to blinded Recall rate for a of reviewed
development, also the to patient completed data worth readers been that with plan for imipridones diligence. note NIH-funded We should performed our patients and trial. We're first as first-in-human also had other without This continuing adjudication, under data, a third toxicity. enrolling treated second as review announce of a the our two part cohort necessary. using currently expert half year will blinded We in in to pipeline this with the dose-escalation be do It's assessment ONCXXX ONCXXX. those are has own ONCXXX I new results. imaging to dose-limiting an the in of mentioning progress be
we've Brown with preclinical on So meantime, cohort. on we work moved are from the ONCXXX the second In to University. support continuing the
to Let to on Melemed, in more our over now first the the Allen, me color data cohort give Dr. a little from call the hand COVID-XX trial.
